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SUMMARY:
Structural and quantitative changes at the polypeptide chains of haemoglobin lead to defective  red
blood cells with a life span 1/5th of the normal, a much smaller capacity  of oxygen saturation, and a less
pliable structure that easily deforms in situations of hypoxia, stress, acidosis, dehydration, cold and pro-
longed physical effort etc. Multi-organ vaso-occlusion and hypoxia ensues, causing severe bone pains,
sequestration, infarction and anaemia. Increased physiologic demands of pregnancy, aggravate falciformation
resulting to poor perfusion of the placenta predisposing to preterm pregnancy loss, intrauterine growth
retardation, pre-eclampsia, severe anaemia and increased perinatal and maternal morbidity and mortality.
Urinary tract, respiratory and bone infections, as well as cardiac and neurologic complications are common.
Treatment is preventive and symptomatic. It aims at reducing high risk combinations, and a meticulous
follow-up to prevent the woman from developing complications and not dying from these complications.
Though vasso-occlusive pain crises and severe anaemia may be fatal they may be remedied by generous use
of analgesics, adequate hydration and exchange transfusion. Sickle cell anaemia the most common of the
three major haemoglobinopathies is more frequent with individuals of African descent, haemoglobin C is
more predominant in the coast of Africa west of the river Niger while  alpha thalassemia and beta thalassemia
haemoglobin are frequent in the Mediterranean and Southeast Asian countries respectively.
KEY WORDS: Sickle cell anaemia - Haemoglobin S – Haemoglobin - Thalassemia haemoglobin –
Haemoglobinopathy – Pregnancy- Vaso-occlusion - Bone pain crises -  Exchange transfusion.
RESUME:
Les modifications qualitatives et quantitatives sur les sous-unités protéiques de l’hémoglobine
provoquent plusieurs types d’altérations du globule rouge: la réduction de sa durée de vie d’environ 1/5eme
de la normale, la réduction de  sa saturation en oxygène, et la déformation et fragilisation des hématies. La
vaso-occlusion  et l’hypoxie provoquent de graves douleurs osseuses, la séquestration des globules rouges
dans les organes, les infarctus et l’anémie.  L’augmentation  des besoins liés à la grossesse  aggrave la
falciformation.  La réduction de la perfusion placentaire  qui en découle prédispose la femme drépanocytaire
aux situations de fausses couches, de retard de croissance, de pré-éclampsie ou à des anémies sévères. L’on
note également, une augmentation de la morbidité puis de la mortalité  périnatale et maternelle. Les infec-
tions urinaires respiratoires ou osseuses sont fréquemment retrouvées ainsi que les complications cardia-
que et neurologique. Le traitement est préventif et symptomatique; son but étant de décourager les unions
entre individus à haut risque et d’assurer à la future mère  un suivi méticuleux afin de  lui éviter de dévelop-
per des  complications et d’en mourir. La crise vasoocclusive et l’anémie sévère peuvent  être  fatales.
Cependant  l’usage des analgésiques, une bonne réhydratation  et des transfusions sanguines peuvent remé-
dier à la situation. L’hémoglobine S  qui est la plus fréquente  des  trois  types majeurs des ‘hémoglobinopathies
est  fréquente chez les individus descendant  des Africains; l’hémoglobine C se retrouve plus sur la cote
africaine à L’Ouest du fleuve  Niger. Les thalassémies  alpha et bêta  quant à elles sont fréquentes en
méditerranée et au sud –Est asiatique respectivement.
MOTS-CLES:  Drépanocytose- Hémoglobine S –Hémoglobine C – Hémoglobine thalassémique – Gros-
sesse – Vaso-occlusion – Douleurs osseuses – Exsanguino transfusion
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Sickle cell disease (SCD) embraces a
variety of combinations in which the sickling gene
is present with another abnormal gene affecting
haemoglobin production or structure. Normal
adult and foetal haemoglobin are called A and F,
respectively[1]. Sickle cell haemoglobin is called
S: there are many other abnormal haemoglobins
of which haemoglobin C [1] and thalassemia are
of particular importance in obstetrics when they
occur together with S.  The normal haemoglobin
is composed of four sub units of polypeptide
chains (alpha, beta, delta, and gamma chains) each
of which carries a haem molecule [2] . The normal
haemoglobin contains, 95-98% of adult
haemoglobin (HbAorHbA1), 1.5% of
haemoglobin A2 (HbA2) and 0.5% of foetal
haemoglobin (HbF) [1]. Most
haemoglobinopathies, involve structural changes
caused by a single point mutation in amino acids
in the haemoglobin molecule as in haemoglobin
S and haemoglobin C.  In haemoglobin S the
amino acid glutamic acid at the sixth  position of
the N terminal of the beta chain is replaced by
valine whereas  in haemoglobin C glutamic acid
is replaced by lysine instead. Alpha and beta
thalassemia haemoglobinopathies  are caused by
alterations in quantity ( gene deletion) of these
haemoglobin chains[3] . The three major
haemoglobinopathies are  sickle cell anaemia (Hb
SS), sickle cell haemoglobin C disease, and sickle
cell thalassemia  disease. Other less common
haemoglobinopathies include , haemoglobin D,
haemoglobin E , haemoglobin O-ARAB,
haemoglobin Constant-spring, Unstable
haemoglobin, and haemoglobin M[1] .
II- HISTORY
Sickle cell disease (SCD) had probably
existed for long in Africa as many tribes have a
local name for it. Research through oral history
demonstrated that this disease had existed in nine
generations of a Ghanaian family since 1670 [3]
The sickling red blood cell was probably first dis-
covered in 1904 when the blood of a black sick
student  from Grenada was examined under the
microscope[4]. From an evolutionary standpoint,
haemoglobin S mutation appears to have provided
some protection from blood born diseases such
as malaria. Patients with haemoglobin AS and
haemoglobin SS are less susceptible to infections
from falciparum malaria. The significance of a
haemoglobin C mutation is less clear, but may
represent a similar protection from infectious
haemolytic diseases such as malaria [3].
III-EPIDEMIOLOGY
The sickle gene is found more frequently
in individuals of African-origin. Approximately
one of every 12 African-American has the sickle
trait (haemoglobin AS)[5].  Haemoglobin C is
more predominant in the west coast of Africa. It
has its highest incidence  in northern Ghana,
Nigeria, and in Burkina Faso haemoglobin C
heterozygotes are found in frequencies
approaching 30%. On all sides of this zone of
high incidence the frequency falls, and to the east
it stops abruptly at the Niger river [1]. Alpha-
thalassemia and ß-thalassemia genes are found
with an increased frequency in individuals of
Mediterranean / Arabic descent, and Southeast
Asian ancestry, respectively [3].
Haemoglobinopathies are rear among northern
Europeans, Japanese, Inuit (Eskimos), Native
Americans, and those of Mexican and Korean
descent [2 of 2 (6)]. Because of the autosomal
recessive pattern of inheritance of these
haemoglobinopathies, the risk of an SS offspring
of parents with traits of this disease is 1/4.
However the incidence of SS disease in pregnancy
is less than predicted from the number of births
of children with SS,  because a high percentage
of affected children die prior to reaching
reproductive age[5].
IV-PATHOPHYSIOLOGY:
Sickle cell anaemia (HbSS), the most
common of the haemoglobinopathies, is an
autosomal recessive genetic disease that results
from the substitution of valine for glutamic acid
at position 6 of the beta-globin gene, leading to
production of a defective form of haemoglobin,
haemoglobin S (HbS)[7] . Deoxygenation of the
haem moiety of HbS leads to hydrophobic
interactions between adjacent HbS molecules,
which then aggregate into larger polymers,
distorting the red blood cell into the classic sickle
shape[7].
The major consequence of this sickle shape is that
red blood cells become much less deformable;
therefore, they obstruct the microcirculation. Tis-
sue hypoxia, which promotes further sickling, re-
sults. Sickle-shaped red blood cells are rapidly
hemolysed and have a very short life span of only
10-20 days as compared to the life span of 120
days  for normal red blood cells  [7] . With rapid
haemolysis of the red blood cells the bone mar-
row reacts by stepping up reticulocytosis by about
2%[1]. Certain conditions such as stress, hypoxia,
acidosis, dehydration, hyperthemia, cold, pro-
longed physical effort, pregnancy, labour and
pueperium and alcohol intoxication, may precipi-
tate falciformation [1].
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Since the earliest description of pregnancy in
patients with SCD by Kobak, documentation of
complications associated with pregnancy in sickle
cell diseases have continued to accumulate [8-
10]. Although haemoglobin S trait,
haemoglobin C trait, and alpha-thalassemia do
not pose significant risks to a pregnant patient,
certain complications such as urinary tract
infections and anaemia are more common in these
patients. Sickle cell disease (haemoglobin SS
disease), haemoglobin SC disease, haemoglobin
C disease (haemoglobin CC disease), and beta-
thalassemia are associated with an increased risk
of serious pregnancy morbidity and mortality. The
contribution of sickle cell  disease to maternal
mortality  is substantial amongst populations
where the disease is common[1] .  The principle
pregnancy complications encountered with
patients with these major haemoglobinopathies
include frequent urinary tract infections (cystitis,
pyelonephritis), respiratory infections, and vaso-
occlusive crisis[1,2,3,8]. The complications are
at times so severe that it is worth questioning
whether patients with these haemoglobinopathies
should be counselled against attempting
pregnancy.
V-THE EFFECT OF SICKLE CELL
DISEASE  ON PREGNANCY.
Placental Changes
The placenta shows abnormalities in histopathol-
ogy, weight, size, location and adherence to uter-
ine wall. Abruptio placenta may be caused by the
vasoocclusive process with thrombosis of de-
cidual arterioles, and subsequent venous haem-
orrhage.  Pathological changes in the placenta in-
cluding fibrosis, infarctions, calcifications, fibrin
deposits, and oedema may be enhanced in sickle
cell disease[8].  These placental changes may con-
tribute to increased abortions, intrauterine deaths,
toxaemia of pregnancy, preterm labour and pre-
mature delivery, and the increased perinatal mor-
bidity and mortality associated with SCD in preg-
nancy.
Abortions
Microvascular damage to the placenta by sickling,
the general health of the patient, and the use of
alcohol, tobacco and narcotics during pregnancy
may increase the frequency of spontaneous
abortions. The frequency of abortions in pregnant
women with SCD though not very different from
the normal  population[8], is estimated at 20 to
40 % (19% in Yaounde, 26% in Cotonou and 40%
in Abidjan) [2].
Intrauterine Growth Retardation
That maternal anaemia and haemoglobin
concentration less than 6 gm is associated with
growth retardation is controversial[8].
Intrauterine growth retardation may be brought
about by hypoperfusion and hypoxia of the
placental membranes resulting from  occlusion
of the arterioles of the decidua of the placenta.
The early occurrence in SCD of placental
problems such as calcification, infarcts due to
direct placental injury, abruptio placenta,
placenta praevia and toxaemia also cause IUGR
and may explain why prophylactic transfusion
started later in pregnancy cannot prevent
complications[1,2,8]. Vasospasm of the uterine
vasculature and hypoxaemia in the placental
bed cause proteinuria and decreased uterine
blood flow, resulting in intrauterine growth
retardation The nutritional status of patients
with sickle cell disease which may be altered
by frequent hospitalisation for acute and
chronic events, can interfere with appropriate
weight gain. Similarly, the prolonged use of
narcotics for the treatment of pain may have
vasoconstrictive effects on the placental vessels
contributing to adverse effect on foetal
nutrition[8].  It is estimated that the frequency
of foetal hypotrophy  is 30%[2].
Pre-Term Labour and Premature Delivery
Both preterm labour and premature delivery
have been identified as a common occurrence
in sickle cell disease[8-9]. 30% of premature
deliveries are related to hyperthemia, infection
and anaemia, in particular with SC-thalassemia
and  S-thalassemia (2). Increased production of
prostaglandin has been implicated along with
anaemia, abruptio placenta praevia and toxae-
mia which are all linked with preterm labour.
Multiple gestation, infection, urinary tract in-
fection, intrauterine infection and use of nar-
cotics, smoking, chorioamnionitis and sexually
transmitted diseases have also been implicated
in the increased perinatal mortality that has
been reported[8].
Pre-eclampsia
Toxaemia of pregnancy is a frequent occurrence
in patients with SCD. There is a fivefold
increase in frequency of pre-eclampsia in sickle
cell disease. The mechanism remains unclear,
and multiple etiologic factors such as excessive
placental mass, placental ischaemia, imbalance
of prostaglandins and endothelial injury have
been implicated[8]. Nulliparity, lower socio-
economic status, multiple gestation,
hypertension, and previous history of pre-
eclampsia are factors frequently associated with
pre-eclampsia [1,2,8,11].
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The blood pressure in non-pregnant individuals
with sickle cell anaemia tend to run at lower levels
than that of normal controls (90/50 to 110/70).
During normal pregnancy blood pressure
falls until 20 weeks of intrauterine pregnancy and
thereafter rises to pre-pregnancy levels. Many
obstetricians note thatblood pressures of 125/75
and higher are associated with increased perinatal
morbidity after 36 weeks of gestation. Toxaemia
is treated with bed rest; frequent monitoring and
hospitalisation is recommended. If toxaemia is
mild, delivery of the foetus is recommended if
foetal survival is estimated over 95% (gestational
age equal to or greater than 32 weeks). When
toxaemia is very severe, delivery is recommended
after clinical stabilisation of the patient. The
management of the pre-eclampsia depends on the
severity of the symptoms and the gestational age.
In the stable compliant patient mild pre-eclampsia
requires close observation with bed rest and
maternal surveillance. The goals are to minimise
maternal morbidity and to optimize the perinatal
outcome. If the patient can be continued on bed
rest and delivery can occur after 32 weeks, the
outcome is significantly improved. Expedited
delivery is recommended for uncontrolled
hypertension. Signs of toxaemia, low platelet
count, elevated liver enzymes, pulmonary oedema,
compromised renal function and headache or
visual changes also require a search for  differential
diagnosis of thrombotic thrombocytopenic
purpura (TTP), haemolytic anaemia, elevated liver
enzymes and low platelets (HELLP syndrome),
haemolytic uremic syndrome (HUS) hypertensive
crisis and cerebrovascular accident (CVA)
associated with sickle cell disease[8].
Perinatal Morbidity and Mortality
There is a wide range of occurrence of
perinatal morbidity and mortality in different
regions around the world ranging between 10-50
per 1000. In Cameroon perinatal mortality is 75
per 1000 [12] while in the United States it is
approximately 18 per 1000 [8]. Neonatal and foe-
tal mortality is observed in 50-80% of cases
especially withSC, S-thalassemia and SC-
thalassemia[2]. Methods to distinguish foetuses
that are at high risk include ultrasound assessment
of intrauterine growth retardation performance of
biophysical profile, uterine umbilical Doppler
blood flow studies and continued monitoring
during labour have reduced the incidence. Close
monitoring, prompt diagnosis and aggressive
treatment of complications during the prenatal and
neonatal period by the efforts of multidisciplinary
teams have contributed to better outcome [7].
Management of sickle cell disease in preg-
nancy
One in sixteen women in Africa die of
complications from pregnancy and childbirth.
Pregnant sickle cell women fall in the category
of  15% pregnancies that are at high risk of
maternal death [7]. Of the estimated 585,000
maternal deaths that occur each year world wide,
over 99
percent occur in the developing world[13]. The
main causes of maternal death in sickle cell
disease are severe anaemia due to folic acid
deficiency, embolism following bone marrow
infarction, and acute sequestration of red blood
cells [1]. Studies in Ibadan suggested that 1 in
10 pregnant women with sickle cell disease may
die as a result of complications of the disease,
but the risks can certainly be minimised by
special measures [ 1].
Strategically, there are  three fundamental ways
in which maternal deaths can be prevented [14]:
1. Through preventing a woman from
becoming pregnant.
2. Through preventing a woman from
developing a complication that can lead to her
death.
3. Through preventing a woman from dying
from a pregnancy complication.
Preventing a woman from becoming pregnant
or having an affected baby.
Though individuals are at liberty to
freely choose their spouses, the burden from
high morbidity and mortality of their off springs
from SCD is so enormous that proper prenuptial
counselling and examination are necessary to
avoid high risk combinations.  The
investigations include [ 5]:
a) Haemoglobin electrophoresis for the
diagnosis of haemoglobins A, S, and C.
b) Solubility testing for observing sickled cells
may be negative for individuals with
haemoglobin B, C, V, E and thalassemia trait
carriers.
c) Investigations for beta thalassemia. Red cell
indices, mean corpuscular volume (MCV)  less
than 80fl when iron deficiency anaemia has been
ruled out. An elevated haemoglobin A2 more
than 3.5% or haemoglobin F of 1% to 5%
signifies beta thalassemia.
d) For alpha thalassemia DNA based testing can
detect alpha globin gene deletions that are
characteristic of alpha thalassemia.
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When both parents are carriers of the trait,
they have the option of using contraception in
order not  to have children or run the 25% risk of
giving birth  to an SS offspring. Oral
contraceptives as well as contraceptive agents
administered intramuscularly and barrier methods
are all acceptable choices for women with
SCD[15].
Few studies have evaluated oral contraceptives,
but none showed adverse effects[16].  Intrauterine
devices are not optimal, since they may be
associated with uterine bleeding and infection in
any user, regardless of the presence of SCD.
Contraception and SCD [15].
 Also the pregnant woman could be offered
prenatal screening to detect the haemoglobin  of
the foetuses. She could  do: a) Chorionic villus
sampling and or b) amniocentesis. The decision
to continue or terminate the pregnancy is fraught
with many implications of medico-legal, moral
and religious considerations. In Cameroon though
abortions are allowed in case of risks to a
woman’s life, foetal defects or in the case of rape
or incest[17], it is not clear if a foetus affected
with SS is enough “foetal defect” to be considered
a reasonable medical reason for late abortion.
Even in the most liberal country like USA where
abortion has been legalised for long, only recently
(early November 2003) a bill was  passed
prohibiting late abortions. Abortion is far from
meeting the aspirations of patients and the
medical team in reducing the burden  of sickle
cell disease. Fortunately a group of  researchers
recently devised a new technique of screening
called pre-implantation genetic diagnosis (PGD)
in which the genetic material of embryos are
tested for SS prior to implantation. They reported
a successful case of PGD prior to embryo transfer
after in vitro fertilisation[18].
Here is how the authors summarise their
study[19]:
“In summary, this is the first unaffected pregnancy
and delivery after successful PGD for sickle cell
anaemia. Our results demonstrate that PGD for
the detection of sickle cell anaemia is a powerful
diagnostic tool for carrier couples who desire a
healthy child but wish to avoid the difficult
decision of whether to abort an affected foetus.
The procedure, successfully used in this case, may
also be applied to other monogenic disorders ....
Given the current methods and relatively high
cost of the procedure, it is unlikely (however)
that PGD will totally replace prenatal testing”.
Preventing a woman from developing a com-
plication that can lead to her death.
The SS patient before contemplating
pregnancy should be warned  of the aggravating
effect of  SCD crises by pregnancy and the im-
minent risk of  not carrying the pregnancy to
term. She runs the risk of developing  severe
anaemia and toxaemia of pregnancy and as such
the likely hood of several blood transfusions and
caesarean section should be discussed.
The pregnant SS woman is among the 15% of
women likely to have complications in preg-
nancy.
Laboratory investigations.
In addition to routine prenatal laboratory
investigations, base line laboratory studies in-
clude: Complete blood count, reticulocyte count,
haemoglobin electrophoresis, urinalysis, serum
iron, ferritin, total iron-binding capacity, and
creatinine, screening for red-blood cell antibod-
ies, hepatitis B and C, and the human immuno-
deficiency virus [5].
Symptoms, laboratory findings, or history
suggestive of specific organ involvement should
elicit the following work-up[5]:
Cardiac:  Echocardiography, since these patients
can have cardiac dysfunction from ventricular
h y p e r t r o p h y .
Renal : 24-hour urine for volume, creatinine, and
protein in case of renal papillary necrosis that
may lead to haematuria and the inability to con-
centrate urine, pyelonephrosis.
Pulmonary: Pulmonary function tests. They may
have infarction, pulmonary hypertension, bone
marrow infarction leading to fat embolisation.
Cerebral: Head computerised axial tomography
(CAT) or magnetic resonance imaging (MRI) be-
cause of cerebral vascular accidents.
Treatment
As of date there is no curative treatment
for falciformation [2]. The treatment is largely
symptomatic and consists of:
1) Good dietary habits[5].
2) Throughout pregnancy prophylactic folic acid
(1mg daily) should be given and haemoglobin
levels frequently checked[1,5]. Iron supplemen-
tation should be given to SC, and S-beta-
thalassemia patients but not to SS unless ferri-
tin has been measured  [5].
3) When necessary antimalarials should be
given[1]. However there is very little evidence
to support or refute giving routine chemoprophy-
laxis in sickle cell disease in areas where ma-
laria is endemic[20].
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4) Adequate hydration with isotonic glucose, iso-
tonic bicarbonate  and macromolecules when
sick or in labour  (Dextran) [2].
5) Liberal use of analgesics in bone pain crises.
Adequate pain relief is crucial in treating pain-
ful crises. Narcotic analogues are usually nec-
essary. Non steriodal anti inflammatory drugs
should  be used with care especially after 32
weeks of gestation due to risk of closure of the
foetal ductus arteriosus and the development of
oligohydramnios (5). Lawson in his long experi-
ence in Ibadan Nigeria, recommended the use
of heparin if crises occur between onset of la-
bour and 4th day of pueperium. He recommended
that if development of systolic hypertension and
albuminuria indicate imminence of marrow
embolism, heparinisation and  exchange blood
transfusion should be carried out and if the pa-
tient was undelivered the pregnancy should be
terminated if necessary by caesarean section[1].
6) Infection control. Infections are associated
with as many as one third of adult sickle cell
crises. Occurring in tissues susceptible to vaso-
occlusive infarcts (bone, kidney, lung), they
manifest as osteomyelities, urinary tract infec-
tions and pneumonia[5].  Evaluating the patient
for asymptomatic bacteriuria and treating her, if
necessary, is essential[5]. A Cooperative Study
of the clinical course of sickle cell disease
showed that, neo-natal screening, prophylactic
penicillin, and anti-pneumococcal vaccine have
had striking effects on survival [8].
7) Oxygenation. Supplemental oxygen is given
to increase oxygen tension, which may possibly
decrease the intensity of sickling at the capil-
lary level, although its benefits have not yet been
proved in clinical studies [5].
8) Transfusion of packed blood cells. Blood
transfusion is required when the haemoglobin
falls below 6gm %[1]. Straight transfusion in
patients with major haemoglobinopathies is usu-
ally performed to raise the patients hematocrite
to a value between 25% and 30%. Over transfu-
sion may increase blood viscosity and worsen
sickling. Packed red blood cells are the blood
products of choice, since they reduce the risk of
antigen sensitisation. It is common for patients
with major haemoglobinopathies to develop
positive antibody screens from repetitive blood
transfusion[3].  Red blood cell screening for the
most common antigens that cause alloantibodies
(Kell, C, E, S, Fy and JK) so that phenotypically
matched  units will be available for future trans-
fusion therapy, can be done at the first visit[5].
9) Exchange transfusion should be carried out if
acute sequestration crises occur[1].  When Ricks
in 1961 introduced the role of exchange transfu-
sion as treatment, prophylactic transfusion was
accepted as treatment for all women with sickle
cell disease during pregnancy[8]. However, in the
1980s, a randomised trial carried out by Tuck failed
to demonstrate the efficacy of prophylactic trans-
fusion during pregnancy [8].
10) Specific therapeutic trials have been carried
out with hydroxyl urea and cynate of potassium
but their efficacy and secondary effects leave much
to be desired[2]. The aim of hydroxyurea therapy
is to induce production of foetal haemoglobin, and
many patients who have used these treatment have
presented  with less frequent clinical episodes of
painful crisis and improved laboratory parameters.
However hydroxyurea may have detrimental ef-
fects on the foetus. If pregnancy is planned hy-
droxyurea needs to be discontinued[8].
Measures should be taken to avoid the following:
a) Uterotonics such as ergometrine which may ag-
gravate vasoocclusive crisis. b) Transfusion of cold
and whole blood.
c) Hypertonic solutions such as 10 or 30% bicar-
bonate and hypertonic glucose. These may increase
the viscosity of blood and promote falciformation.
d) Diuretics may cause dehydration. e)
Betamimetics should be avoided as much as pos-
sible in threatened premature delivery; instead
natural progesterone should be used [2].
Intrapartum care
1) Parturient should be managed in the left lateral
recumbent position.
2) Pain crisis should be managed with analgesics
and or epidural anaesthesia.
3) Supplemental oxygen should be given. Hypoxia
may compromise cardiac function
4) Adequate hydration is necessary to avoid dehy-
dration.
5) Her BP is monitored constantly. One third of
SS pregnant patients have pregnancy induced hy-
pertension.
6) Foetal monitoring. Detection of evidence of pla-
cental insufficiency requires prompt Caesarean sec-
tion.
7) Transfusion with packed red blood cells should
be considered if haematocrit is less than 20% or if
caesarean section  is envisaged[21].
8) Vaginal delivery is preferable and caesarean sec-
tion delivery is performed for obstetrical indica-
tions.
9) Blood loss during labour should be evaluated
and blood transfusion started if the loss aggravates
anaemia.
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10) Early ambulation. Anti-embolic stockings
and discussion of future pregnancies should be
discussed prior to discharge.
11) Results of the cord blood sample screening
for sickle cell disease  of the infant  should be
made available to the  parents and paediatri-
cian.
To prevent a woman from dying from a preg-
nancy complication.
The follow-up of SCD patients with
pregnancy complications  requires hospitals
equipped with specialised units where basic and
comprehensive emergency obstetrical care can
be provided.
Basic emergency obstetrical care refers to the
ability to manage labour, recognise and refer
patients with abnormal labour patterns, provide
intravenous fluids, medications to stop post-
partum haemorrhage, antibiotics, assisted vagi-
nal delivery, manual
removal of the placenta, management of incom-
plete miscarriage and basic neonatal
resuscitation.Comprehensive emergency ob-
stetrical care refers to the ability to provide
blood transfusions and caesarean sections in ad-
dition to providing basic emergency obstetri-
cal care[14].  With modern obstetrical care, a
maternal death is a rare event. Where modern
obstetrical care is lacking, maternal death rates
can be high, paralleling the maternal death rates
of Europe and North America in the 1700's and
l800’s. In many countries in Africa and several
countries in Asia, there are between 1000 and
1700 maternal deaths per 100,000 live births  a
rate well over 100 times greater than that of the
United States[14]. In Cameroon, one out of
every 26 women have a life time risk of mater-
nal death [12] , the maternal mortality ratio for
the year 1995 was 720 per 100,000 life
births[22] and by 1999 it was 420 per 100,000
life births[23].
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